Feed UTHR
UT

United Therapeutics UTHR · NASDAQ

$533.12 -1.55% (-$8.39)

Market cap
$23.0B
Enterprise value
$21.2B
P/E
17.5x
Forward P/E
18.5x
PEG
1.5x
P/S
7.3x
P/FCF
21.0x
EV/EBITDA
12.8x
ROIC
17.7%
Gross margin
86.1%
Net margin
41.6%
Dividend yield
-
Payout ratio
-
Net debt/EBITDA
-1.1x
Beta
0.56
Free float
91.4%

About the company

United Therapeutics Corporation is an American biotechnology company headquartered in Silver Spring, Maryland. The company focuses on the development and manufacturing of drugs for the treatment of pulmonary arterial hypertension and other pulmonary and vascular-related diseases. Their main drugs include therapies for the treatment of pulmonary arterial hypertension and carcinoid syndrome. United Therapeutics is also involved in research and development of new drug formulations in the field of regenerative medicine and organ transplantation. The company is known for its innovative approach to treating pulmonary diseases and comprehensive research in the field of biotechnology. Shares of United Therapeutics Corporation are publicly traded on the NASDAQ stock exchange.

Sector

Healthcare

Industry

Biotechnology

CEO

Martine A. Rothblatt

Employees

1,400

Headquarters

Silver Spring

Valuation

Is today's price reasonable?

Growth and estimates

Is it growing, and what comes next?

Profitability and quality

How much of the revenue is left, and how well does the company use its capital?

Financial health

Can it carry its debt?

Capital and dividends

What does the company do with the money it earns?

Analysts

What do the professionals think, and is it changing?

Owners and insiders

Who holds the stock, and what is management doing?

Segments

Which part of the company is growing?

Peer comparison

How does it compare with similar companies?

Price and risk

How does the stock behave?

Statements

Every number

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.